» Articles » PMID: 28449560

Assessment of the Latent Adverse Events of Antipsychotic Treatment Using a Subjective Questionnaire in Japanese Patients with Schizophrenia

Overview
Specialty Psychiatry
Date 2017 Apr 29
PMID 28449560
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The adverse effects of antipsychotic agents can have a marked influence on medication adherence. In this study, we.

Methods: Data were collected by interviewing patients using a subjective questionnaire, and the associations between unreported symptoms and background factors were investigated.

Results: A total of 306 patients with schizophrenia or schizoaffective disorder were examined. Their major symptoms were daytime sleepiness (50.0%), weight gain (42.2%), and sexual dysfunction (38.9%). Sexual dysfunction was nominal significantly more common among the patients that had been treated with antipsychotic agent polypharmacy (odds ratio [OR], 2.14; 95% confidence interval [CI], 1.07 to 4.30), and was nominal significantly more common among outpatients (OR, 1.78; 95% CI, 1.02 to 3.13). Only approximately 30% of the patients had reported their symptoms to their physicians.

Conclusion: Patients receiving antipsychotic treatment tolerate some symptoms and do not feel able to report them to their physicians. The most common reason for this is an insufficient patient-physician relationship. Sexual dysfunction is especially hard to identify because it is a delicate problem, and our findings demonstrate that subjective questionnaires are helpful for detecting such symptoms.

Citing Articles

Utilizing questionnaires for medication counselling of patients taking antipsychotics during the COVID-19 pandemic: a single site, community pharmacy-based survey study.

Maehara M, Sugiyama M J Pharm Health Care Sci. 2022; 8(1):34.

PMID: 36474275 PMC: 9727913. DOI: 10.1186/s40780-022-00263-w.


Satisfaction Survey on Antipsychotic Formulations by Schizophrenia Patients in Japan.

Hatano M, Takeuchi I, Yamashita K, Morita A, Tozawa K, Sakakibara T Clin Psychopharmacol Neurosci. 2021; 19(4):610-617.

PMID: 34690116 PMC: 8553540. DOI: 10.9758/cpn.2021.19.4.610.


A community pharmacist's intervention in antipsychotic drug-induced sexual dysfunction in a patient with schizophrenia.

Maehara M, Sugiyama M Clin Case Rep. 2021; 9(4):2074-2076.

PMID: 33936642 PMC: 8077334. DOI: 10.1002/ccr3.3946.


Rehospitalization Risk of Receptor-Affinity Profile in Antipsychotic Drug Treatment: A Propensity Score Matching Analysis Using a Japanese Employment-Based Health Insurance Database.

Takekita Y, Inoue S, Baba K, Nosaka T Neuropsychiatr Dis Treat. 2020; 16:2871-2879.

PMID: 33299315 PMC: 7721289. DOI: 10.2147/NDT.S276030.


Randomised controlled trial of gradual antipsychotic reduction and discontinuation in people with schizophrenia and related disorders: the RADAR trial (Research into Antipsychotic Discontinuation and Reduction).

Moncrieff J, Lewis G, Freemantle N, Johnson S, Barnes T, Morant N BMJ Open. 2019; 9(11):e030912.

PMID: 31780589 PMC: 6887002. DOI: 10.1136/bmjopen-2019-030912.


References
1.
Fujimaki K, Takahashi T, Morinobu S . Association of typical versus atypical antipsychotics with symptoms and quality of life in schizophrenia. PLoS One. 2012; 7(5):e37087. PMC: 3353903. DOI: 10.1371/journal.pone.0037087. View

2.
Wieck A, Haddad P . Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review. Br J Psychiatry. 2003; 182:199-204. DOI: 10.1192/bjp.182.3.199. View

3.
Park Y, Kim Y, Lee J . Antipsychotic-induced sexual dysfunction and its management. World J Mens Health. 2013; 30(3):153-9. PMC: 3623530. DOI: 10.5534/wjmh.2012.30.3.153. View

4.
De Hert M, Correll C, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I . Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011; 10(1):52-77. PMC: 3048500. DOI: 10.1002/j.2051-5545.2011.tb00014.x. View

5.
Marder S, Meibach R . Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994; 151(6):825-35. DOI: 10.1176/ajp.151.6.825. View